|
Kidney Calculi
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis, and this outcome may provide a good potential therapeutic target for nephrolithiasis.
|
31680444 |
2020 |
|
Nephrolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis, and this outcome may provide a good potential therapeutic target for nephrolithiasis.
|
31680444 |
2020 |
|
Retinoblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We also found that HOXA11-AS could serve as a competing endogenous RNA (ceRNA) that inhibited miR-506-3p expression, which regulated its downstream target NIMA-related kinase 6 (NEK6) in RB.
|
31123409 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HOXA11-AS was highly expressed in liver cancer tissues and cell lines, which was closely related with poor prognosis in patients with liver cancer.
|
31099097 |
2019 |
|
Papillary thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, this research supports the first evidence that lncRNA HOXA11-AS-reguated miR-761 plays a functional role in inhibiting PTC progression by targeting TRIM29 and represent a promising therapeutic strategy for patients with PTC.
|
31814890 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HOXA11-AS was highly expressed in liver cancer tissues and cell lines, which was closely related with poor prognosis in patients with liver cancer.
|
31099097 |
2019 |
|
Malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HOXA11-AS was highly expressed in liver cancer tissues and cell lines, which was closely related with poor prognosis in patients with liver cancer.
|
31099097 |
2019 |
|
Malignant Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The LncRNA HOXA11-AS expression in cases of high-grade glioma was significantly higher than that in cases of low-grade.
|
30064227 |
2019 |
|
Cardiac fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, the present study suggested that the lncRNA HOXA11‑AS may be a potential therapeutic target against cardiac fibrosis, and provided a novel insight into the diagnosis and treatment of clinical cardiac fibrosis.
|
30720066 |
2019 |
|
High grade glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The LncRNA HOXA11-AS expression in cases of high-grade glioma was significantly higher than that in cases of low-grade.
|
30064227 |
2019 |
|
Diabetes Mellitus
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Similarly, HOXA11-AS expression was also significantly increased in carotid arteries of DM mice compared with that of non-DM mice.
|
30402857 |
2018 |
|
Endometriosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, the study findings suggest that HOXA11-AS1 lncRNA may play a role in the development of peritoneal endometriosis, but HOXA11-AS1 may not influence endometrial receptivity in endometriosis-associated infertility.
|
29017417 |
2018 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results provide new insight into the molecular mechanism by which lncRNA HOXA11-AS1 is involved in adipogenesis and may have implications for the treatment of obesity and associated disorders.
|
29217197 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, knockdown of HOXA11-AS caused positive changes in cell activities of LUAD.
|
30099826 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the current study, our data showed that the expression of HOXA11-AS was significantly upregulated in clear cell renal cell carcinoma (ccRCC) tissues and cell lines.
|
29953617 |
2018 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of long non-coding RNA HOXA11-AS is correlated with progression of laryngeal squamous cell carcinoma.
|
29511452 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the function of HOXA11-AS in lung cancer remains unclear.
|
29616096 |
2018 |
|
Malignant neoplasm of kidney
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our findings suggested that HOXA11-AS could serve as potential therapeutic target for the treatment of renal cancer.
|
29953617 |
2018 |
|
Malignant Squamous Cell Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, the current data indicated that HOXA11-AS plays an oncogenic role in the cellular processes of LSCC and serve as a novel marker and a potential therapeutic target in LSCC patients.
|
29511452 |
2018 |
|
Vascular inflammations
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In VECs, low expression of HOXA11-AS can inhibit the expression of TNF-α-induced pro-inflammatory genes and PDGF-induced vascular inflammation-related genes.
|
30402857 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
HOXA11-AS, LINC00964 and MALAT1 might be potential circulating biomarkers for the early detection of HNSCC in the future.
|
30355951 |
2018 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the function of HOXA11-AS in lung cancer remains unclear.
|
29616096 |
2018 |
|
Renal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our findings suggested that HOXA11-AS could serve as potential therapeutic target for the treatment of renal cancer.
|
29953617 |
2018 |
|
Diabetic arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
HOXA11-AS may participate in DAA by activating the PI3K/AKT pathway to regulate inflammation in VSMCs and VECs.
|
30402857 |
2018 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Homeobox A11 antisense (HOXA11-AS), a newly identified lncRNA, is up-regulated in various carcinomas.
|
28942241 |
2017 |